about
MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseasesNew potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticlesIdentification and Characterization of a Novel Family of Cysteine-Rich Peptides (MgCRP-I) from Mytilus galloprovincialis.Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome.Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort.Glucocorticoid Receptor Interacting Co-regulators: Putative Candidates for Future Drug Targeting Therapy.RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.Effects of Two Fullerene Derivatives on Monocytes and Macrophages.Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq.Pharmacotranscriptomic biomarkers in glucocorticoid treatment of pediatric inflammatory bowel disease.Pharmacokinetics and pharmacodynamics of thiopurines in an in vitro model of human hepatocytes: Insights from an innovative mass spectrometry assay.Carbamazepine-induced thrombocytopenic purpura in a child: Insights from a genomic analysis.Role of the Long Non-Coding RNA Growth Arrest-Specific 5 in Glucocorticoid Response in Children with Inflammatory Bowel Disease.Imidazo[2,1-b]benzothiazol Derivatives as Potential Allosteric Inhibitors of the Glucocorticoid Receptor.Differential expression of GAS5 in rapamycin-induced reversion of glucocorticoid resistance.High-Throughput Sequencing of microRNAs in Glucocorticoid Sensitive Paediatric Inflammatory Bowel Disease Patients.Pro-inflammatory effects of palytoxin: an study on human keratinocytes and inflammatory cellsAzathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants.Theophylline as a precision therapy in a young girl with PIK3R1 immunodeficiencyThe non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patientsLong Non-Coding RNA GAS5 and Intestinal MMP2 and MMP9 Expression: A Translational Study in Pediatric Patients with IBDRole of tristetraprolin phosphorylation in paediatric patients with inflammatory bowel diseaseEmerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric PatientsCauses of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic StudySedation and analgesia in children with cerebral palsy: a narrative reviewDetermination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel DiseaseExpression Pattern of Long Non-coding RNA Growth Arrest-specific 5 in the Remission Induction Therapy in Childhood Acute Lymphoblastic LeukemiaTherapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel diseaseMIF plasma level as a possible tool to predict steroid responsiveness in children with idiopathic nephrotic syndromePharmacogenetics of treatments for inflammatory bowel disease
P50
Q27011618-07A3F998-D74C-4BD6-8F09-6CEBA13C9A4FQ27306995-7E0749E7-2FD8-4EF6-9AED-F8FBF3F12093Q35706398-22E83936-79D3-4742-8562-9F4625040270Q38595273-0CF7FEA4-0D56-4051-9149-52A91B114236Q38620025-314F640C-9A95-4764-B118-119A358EC787Q38788926-69CBF274-E2ED-46CA-9E6F-B0203B786599Q38838114-E0F9B830-CA7F-413C-A8FE-EDC9584A0AF0Q38862277-FA08CA3E-B4BB-4344-B895-2E106B1832E5Q39078675-2E79C806-6D15-43D0-83F2-C62304AF6A11Q47652863-744BE4A2-F7F0-49F2-A351-C405273B326AQ50159341-4E0EA140-1303-49F2-9B03-69BAA1629D30Q50505903-8B865FEB-6161-49A1-9A60-306901CF6F28Q50525836-4F3FAD58-5939-413C-896F-3FC4DC2BE9A8Q52579078-5FD2C95C-617B-4E53-AAD6-3DA619FD049BQ53792292-B868033C-7175-4C4C-8785-B6105FDB1D47Q54089688-372BCF35-9994-440E-8264-EF9891EF70F9Q61415639-E74320B3-5E10-44D8-9920-D0C2B5D29FFAQ64966477-980D9E3B-292F-4CF2-AB00-50F2D54C3708Q87979218-C2589FD9-6CA8-4242-B278-D2E1D2A6E4CDQ90281699-1187E769-4144-4681-A3C1-CD5A1B5D396DQ90946525-4561683A-B08D-460E-9808-9FED1A1B45DFQ90979275-0A6F4241-5803-4E48-8C96-B1458534E656Q91055044-7BA237B6-BE5C-4F57-9776-9A86AF6B3798Q91425133-6545BE35-7236-412C-97D5-C45806DC07EDQ92102567-51502CE3-6AA5-444E-A2BC-7D5300ECA5DEQ92437294-474386AA-13DE-4A25-9851-E12D68646FC6Q92477714-A84857E7-A2AB-4519-B3B5-3609E71BDA02Q92612397-39085CE5-AA8C-4148-BE4D-FD0E0D96B312Q92971024-553D917C-EAC3-4055-8CB9-AFBF9D1F91C2Q93348268-6788779D-C0FC-4665-83B9-8E39711F6C02
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marianna Lucafò
@ast
Marianna Lucafò
@en
Marianna Lucafò
@es
Marianna Lucafò
@nl
Marianna Lucafò
@sl
type
label
Marianna Lucafò
@ast
Marianna Lucafò
@en
Marianna Lucafò
@es
Marianna Lucafò
@nl
Marianna Lucafò
@sl
prefLabel
Marianna Lucafò
@ast
Marianna Lucafò
@en
Marianna Lucafò
@es
Marianna Lucafò
@nl
Marianna Lucafò
@sl
P106
P1153
55123083400
P21
P31
P496
0000-0003-1355-3782